Epitalon : données probantes, mécanisme et limites

Epitalon, also spelled Epithalon, is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly (AEDG). It was developed as a defined analogue inspired by Epithalamin, an extract of pineal-gland tissue. The two are not the same substance. Epithalamin is a complex tissue extract, while Epitalon is a single defined peptide. Mixing them up is a common source of misattributed claims.

It is not approved as a medicine in the United States or Canada.

Preclinical: in cultured human cells, Epitalon has been reported to increase telomerase (hTERT) activity and lengthen telomeres. This was first described by the originating Russian group. In 2025 an independent group at Brunel University London partly reproduced it in normal human cells in vitro. In the same work, breast cancer cell lines lengthened their telomeres through the alternative lengthening of telomeres (ALT) pathway rather than telomerase. That is a potential cancer-safety signal, not a benefit.

Proposed, not established: changes in clock and circadian gene expression and in-silico DNA binding have been described. Reports on melatonin and antioxidant effects conflict, and some models, such as rat pineal-gland cultures, show no melatonin effect. A 2025 review lists many reported effects but concludes that after about 25 years of study its mechanism of action remains unclear, and that structural studies of the peptide are limited.

Human clinical data are limited to a small number of mostly open-label studies from one research lineage, the St. Petersburg Institute of Bioregulation and Gerontology. Much of it is in Russian, single-center, with short follow-up. A 2025 review describes one human circadian study in 75 women, with placebo and control groups, that reported higher urinary levels of a melatonin metabolite and changes in clock-gene expression. It measured biomarkers, not sleep or health outcomes, and the review does not say whether it was randomized or blinded.

The widely shared claim that Epitalon lowers mortality traces to a 2003 report from the same group. That program gave Epithalamin, the extract, and Thymalin to elderly people, and it did not meet randomized controlled trial standards. It is not evidence about synthetic Epitalon. No randomized, blinded efficacy trial and no human lifespan or mortality trial of Epitalon exists.

Long-term human safety, genotoxicity and carcinogenicity have not been characterized. Because telomere maintenance is also a feature of cancer cells, the 2025 finding that cancer cell lines lengthened their telomeres deserves attention until it is better understood.

FDA says compounded drugs containing Epitalon may pose a risk of immunogenicity for some routes, due to possible aggregation and peptide-related impurities, and that it has not identified safety information for the proposed route. Health Canada warns that unauthorized peptides sold online may contain the wrong amount of active ingredient, contaminants or unlisted ingredients.

Epitalon is not approved by the FDA or Health Canada. FDA lists it among bulk substances nominated for compounding that were placed in category 2 and later withdrawn by the nominators. Health Canada's Drug Product Database lists no product containing it, and its April 2026 advisory names it among seized unauthorized peptide drugs. It is not named on the 2026 WADA Prohibited List, whose section S0 covers substances with no current approval by any government health regulator for human therapeutic use.